OTC Healthcare in France
Euromonitor International's OTC Healthcare in France market report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data, allowing you to identify the sectors driving growth. It identifies the leading companies, the leading brands and offers strategic analysis of key factors influencing the market - be they new product developments, packaging innovations, economic/lifestyle influences, distribution or pricing issues. Forecasts illustrate how the market is set to change.
Get immediate access to strategic market analysis when you buy reports online
Tables: 111 | Publication date: Dec 2007
Why buy this report
- Get insight into trends in market performance
- Pinpoint growth sectors and identify factors driving change
- Identify market and brand leaders and understand the competitive environment
Product coverage
Adult mouthcare; Allergy care; Analgesics; Calming and sleeping products; Child-specific OTC healthcare; Cough; cold and allergy (hay fever) remedies; Digestive remedies; Ear care; Emergency contraception; Eye care; Medicated skin care; NRT Smoking cessation aids; OTC obesity; OTC statins; OTC triptans; Vitamins and dietary supplements; Wound treatments
Executive summary
Slow Growth
The OTC healthcare market in France again saw a disappointing performance by analgesics, cough, cold and allergy (hay fever) remedies, and digestive remedies in 2006. However this negative trend was offset by dynamic sales of vitamins and dietary supplements products, allowing the French OTC market to register a slight increase in sales volumes. France's OTC market remains less significant than those of many other European countries due to the continuing trend for visiting a GP rather than self-medicating.
De-reimbursement Limited Impact
One of the main obstacles to the progress of the OTC market remains French consumers' perceptions regarding the legitimacy and efficacy of delisted and de-reimbursed medicines. Furthermore, manufacturers have tended to raise the price of such products to offset decreasing volume sales. In March 2006, the Haute Autorité de Santé de-reimbursed a further 156 products deemed as being of low therapeutic value. The switches only have a limited impact on OTC sales, and are geared towards addressing the French Social Security deficit.
Pharmacies Stronghold Lessening
A slight shift occurred in the distribution of OTC healthcare during the review period. Pharmacies, the largest distribution channel in France, steadily lost share to parapharmacies, health food shops and direct sales. Vitamins and dietary supplements are the only OTC products distributed via the Internet, due to the highly regulated nature of the market. The share of mass distribution channels, such as grocery outlets, is still low, as the French consumer still prefers to get professional advice when making a purchase and favours other distributors providing such a service.
Changing Mentalities
The change in French mentality towards self-medication is particularly apparent within vitamins and dietary supplements, which saw a buoyant performance in 2006. Other sectors have not benefited as much from the increase in French consumers' personal responsibility towards self-medication. According to AFIPA (Association Française de L'industrie Pharmaceutique pour une Automédication Responsible – French Association for Responsible Self-medication) French doctors and other health professionals' attitudes are also evolving, and they are more often advising purchase of OTC products.
Potential Growth
France has an under-developed self-medication market compared to other European countries, and the potential for growth in the future is significant. Manufacturers are pressing the French government to simplify the legislation governing the OTC market and to create more flexible regulations regarding advertising. The government is expected to continue with its policy of de-reimbursement, with more switches being made, accompanied by public campaigns to inform people about self-medication. Previous campaigns for generics and to encourage limits on the consumption of antibiotics were extremely successful. The French government has announced important reforms based on two principles: increased individual responsibility and the belief that health is not only an expense but also an investment. It has also ordered a report to lay the basis for government decisions on self-medication policy. Although only moderate growth is expected during the forecast period, in the long-term future the French OTC market is expected to grow strongly.
Table of contents
OTC HEALTHCARE IN FRANCE : MARKET INSIGHT
EXECUTIVE SUMMARY
Slow Growth
De-reimbursement Limited Impact
Pharmacies Stronghold Lessening
Changing Mentalities
Potential Growth
KEY TRENDS AND DEVELOPMENTS
OTC Products in Difficult Trading Conditions
Demographic Trends Impact Demand
De-reimbursement: Does it Work?
Economic Growth Increases Visits to Private Doctors
Hectic Lifestyles and Rising Health Awareness Drive Sales
MARKET INDICATORS
Table 1 Life Expectancy at Birth 2001-2006
MARKET DATA
Table 2 Sales of OTC Healthcare by Sector: Value 2001-2006
Table 3 Sales of OTC Healthcare by Sector: % Value Growth 2001-2006
Table 4 OTC Healthcare Company Shares by Retail Value 2002-2006
Table 5 OTC Healthcare Brand Shares by Retail Value 2003-2006
Table 6 Penetration of Private Label by Sector 2002-2006
Table 7 Sales of OTC Healthcare by Distribution Format: % Analysis 2001/2006
Table 8 Sales of OTC Healthcare by Sector and Distribution Format: % Analysis 2006
Table 9 Forecast Sales of OTC Healthcare by Sector: Value 2006-2011
Table 10 Forecast Sales of OTC Healthcare by Sector: % Value Growth 2006-2011
APPENDIX
OTC Registration and Classification
Advertising
Packaging and Labelling
Distribution
De-listing or De-reimbursement
Vitamins and Dietary Supplements Registration and Classification
Generics
Consumer Expenditure on Health Goods and Medical Services
Table 11 Consumer Expenditure on Health Goods and Medical Services 2001-2006
DEFINITIONS
Sources
Summary 1 Research Sources
LOCAL COMPANY PROFILES - FRANCE
ARKOPHARMA SA, LABORATOIRES PHARMACEUTIQUES - OTC HEALTHCARE - FRANCE
STRATEGIC DIRECTION
KEY FACTS
Summary 2 Arkopharma SA, Laboratoires Pharmaceutiques: Key Facts
Summary 3 Arkopharma SA, Laboratoires Pharmaceutiques: Operational Indicators 2004-2006
COMPANY BACKGROUND
PRODUCTION
COMPETITIVE POSITIONING
Summary 4 Arkopharma SA, Laboratoires Pharmaceutiques: Competitive Position 2006
BEAUFOUR-IPSEN SA - OTC HEALTHCARE - FRANCE
STRATEGIC DIRECTION
KEY FACTS
Summary 5 Beaufour-Ipsen SA: Key Facts
Summary 6 Beaufour-Ipsen SA: Operational Indicators 2004-2006
COMPANY BACKGROUND
PRODUCTION
Summary 7 Beaufour-Ipsen SA: Production Statistics 2006
COMPETITIVE POSITIONING
Summary 8 Beaufour-Ipsen SA: Competitive Position 2006
JUVA SANTé, LABORATOIRES - OTC HEALTHCARE - FRANCE
STRATEGIC DIRECTION
KEY FACTS
Summary 9 Juva Santé, Laboratoires: Key Facts
Summary 10 Juva Santé, Laboratoires: Operational Indicators 2004-2006
COMPANY BACKGROUND
PRODUCTION
Summary 11 Juva Santé, Laboratoires: Production Statistics 2006
COMPETITIVE POSITIONING
Summary 12 Juva Santé, Laboratoires: Competitive Position 2006
LABORATOIRES MARTIN-JOHNSON & JOHNSON-MSD SAS - OTC HEALTHCARE - FRANCE
STRATEGIC DIRECTION
KEY FACTS
Summary 13 Laboratoires Martin-Johnson & Johnson-MSD SAS: Key Facts
Summary 14 Laboratoires Martin-Johnson & Johnson-MSD SAS: Operational Indicators 2004-2006
COMPANY BACKGROUND
COMPETITIVE POSITIONING
Summary 15 Laboratoires Martin-Johnson & Johnson-MSD SAS: Competitive Position 2006
PFIZER SANTé GRAND PUBLIC - OTC HEALTHCARE - FRANCE
STRATEGIC DIRECTION
KEY FACTS
Summary 16 Pfizer Santé Grand Public: Key Facts
Summary 17 Pfizer Santé Grand Public: Operational Indicators 2004-2006
COMPANY BACKGROUND
PRODUCTION
COMPETITIVE POSITIONING
Summary 18 Pfizer Santé Grand Public: Competitive Position 2006
PIERRE FABRE SA, LABORATOIRES - OTC HEALTHCARE - FRANCE
STRATEGIC DIRECTION
KEY FACTS
Summary 19 Pierre Fabre SA, Laboratoires: Key Facts
Summary 20 Pierre Fabre SA, Laboratoires: Operational Indicators 2004-2006
COMPANY BACKGROUND
PRODUCTION
Summary 21 Pierre Fabre SA, Laboratoires: Production Statistics 2006
COMPETITIVE POSITIONING
Summary 22 Pierre Fabre SA, Laboratoires: Competitive Position 2006
THéRAPLIX SA - OTC HEALTHCARE - FRANCE
STRATEGIC DIRECTION
KEY FACTS
Summary 23 Théraplix SA: Key Facts
Summary 24 Théraplix SA: Operational Indicators 2004-2006
COMPANY BACKGROUND
COMPETITIVE POSITIONING
Summary 25 Théraplix SA: Competitive Position 2006
UPSA, LABORATOIRES - OTC HEALTHCARE - FRANCE
STRATEGIC DIRECTION
KEY FACTS
Summary 26 UPSA Conseil SAS: Key Facts
Summary 27 UPSA Conseil SAS: Operational Indicators 2004-2006
COMPANY BACKGROUND
PRODUCTION
COMPETITIVE POSITIONING
Summary 28 UPSA, Laboratoires: Competitive Position 2006
URGO, LABORATOIRES - OTC HEALTHCARE - FRANCE
STRATEGIC DIRECTION
KEY FACTS
Summary 29 Urgo, Laboratoires: Key Facts
Summary 30 Urgo, Laboratoires: Operational Indicators 2004-2006
COMPANY BACKGROUND
PRODUCTION
COMPETITIVE POSITIONING
Summary 31 Urgo, Laboratoires: Competitive Position 2006
ANALGESICS IN FRANCE
HEADLINES
TRENDS
COMPETITIVE LANDSCAPE
PROSPECTS
SECTOR DATA
Table 12 Sales of Analgesics by Subsector: Value 2001-2006
Table 13 Sales of Analgesics by Subsector: % Value Growth 2001-2006
Table 14 Herbal vs Standard Topical Analgesics 2001/2006
Table 15 Analgesics Company Shares by Retail Value 2002-2006
Table 16 Analgesics Brand Shares by Retail Value 2003-2006
Table 17 Forecast Sales of Analgesics by Subsector: Value 2006-2011
Table 18 Forecast Sales of Analgesics by Subsector: % Value Growth 2006-2011
COUGH, COLD AND ALLERGY (HAY FEVER) REMEDIES IN FRANCE
HEADLINES
TRENDS
COMPETITIVE LANDSCAPE
PROSPECTS
SECTOR DATA
Table 19 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Subsector: Value 2001-2006
Table 20 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Subsector: % Value Growth 2001-2006
Table 21 Sales of Decongestants by Type: Value 2001-2006
Table 22 Sales of Decongestants by Type: % Value Growth 2001-2006
Table 23 Sales of Child-specific Cough, Cold and Allergy (Hay Fever) Remedies by Type: Value 2001-2006
Table 24 Sales of Child-specific Cough, Cold and Allergy (Hay Fever) Remedies by Type: % Value Growth 2001-2006
Table 25 Herbal vs Standard Cough, Cold and Allergy (Hay Fever) Remedies 2001/2006
Table 26 Cough, Cold and Allergy (Hay Fever) Remedies Company Shares by Retail Value 2002-2006
Table 27 Cough, Cold and Allergy (Hay Fever) Remedies Brand Shares by Retail Value 2003-2006
Table 28 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Subsector: Value 2006-2011
Table 29 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Subsector: % Value Growth 2006-2011
DIGESTIVE REMEDIES IN FRANCE
HEADLINES
TRENDS
COMPETITIVE LANDSCAPE
PROSPECTS
SECTOR DATA
Table 30 Sales of Digestive Remedies by Subsector: Value 2001-2006
Table 31 Sales of Digestive Remedies by Subsector: % Value Growth 2001-2006
Table 32 Herbal vs Standard Digestive Remedies 2001/2006
Table 33 Digestive Remedies Company Shares by Retail Value 2002-2006
Table 34 Digestive Remedies Brand Shares by Retail Value 2003-2006
Table 35 Forecast Sales of Digestive Remedies by Subsector: Value 2006-2011
Table 36 Forecast Sales of Digestive Remedies by Subsector: % Value Growth 2006-2011
MEDICATED SKIN CARE IN FRANCE
HEADLINES
TRENDS
COMPETITIVE LANDSCAPE
PROSPECTS
SECTOR DATA
Table 37 Sales of Medicated Skin Care by Subsector: Value 2001-2006
Table 38 Sales of Medicated Skin Care by Subsector: % Value Growth 2001-2006
Table 39 Herbal vs Standard Medicated Skin Care 2001/2006
Table 40 Medicated Skin Care Company Shares by Retail Value 2002-2006
Table 41 Medicated Skin Care Brand Shares by Retail Value 2003-2006
Table 42 Acne Treatments Brand Shares by Retail Value 2003-2006
Table 43 Hair Loss Treatments Brand Shares by Retail Value 2003-2006
Table 44 Forecast Sales of Medicated Skin Care by Subsector: Value 2006-2011
Table 45 Forecast Sales of Medicated Skin Care by Subsector: % Value Growth 2006-2011
VITAMINS AND DIETARY SUPPLEMENTS IN FRANCE
HEADLINES
TRENDS
COMPETITIVE LANDSCAPE
PROSPECTS
SECTOR DATA
Table 46 Sales of Vitamins and Dietary Supplements by Subsector: Value 2001-2006
Table 47 Sales of Vitamins and Dietary Supplements by Subsector: % Value Growth 2001-2006
Table 48 Sales of Vitamins by Type: Value 2001-2006
Table 49 Sales of Vitamins by Type: % Value Growth 2001-2006
Table 50 Vitamins and Dietary Supplements Company Shares by Retail Value 2002-2006
Table 51 Vitamins and Dietary Supplements Brand Shares by Retail Value 2003-2006
Table 52 Vitamins Brand Shares by Retail Value 2003-2006
Table 53 Sales of Dietary Supplements by Type: Value 2001-2006
Table 54 Sales of Dietary Supplements by Type: % Value Growth 2001-2006
Table 55 Dietary Supplements Brand Shares by Retail Value 2003-2006
Table 56 Forecast Sales of Vitamins and Dietary Supplements by Subsector: Value 2006-2011
Table 57 Forecast Sales of Vitamins and Dietary Supplements by Subsector: % Value Growth 2006-2011
NRT SMOKING CESSATION AIDS IN FRANCE
HEADLINES
TRENDS
COMPETITIVE LANDSCAPE
PROSPECTS
SECTOR INDICATORS
Table 58 Number of Smokers by Gender 2001-2006
SECTOR DATA
Table 59 Sales of Smoking Cessation Aids by Subsector: Value 2001-2006
Table 60 Sales of Smoking Cessation Aids by Subsector: % Value Growth 2001-2006
Table 61 Smoking Cessation Aids Company Shares by Retail Value 2002-2006
Table 62 Smoking Cessation Aids Brand Shares by Retail Value 2003-2006
Table 63 Forecast Sales of Smoking Cessation Aids by Subsector: Value 2006-2011
Table 64 Forecast Sales of Smoking Cessation Aids by Subsector: % Value Growth 2006-2011
EYE CARE IN FRANCE
OVERVIEW
SECTOR DATA
Table 65 Sales of Eye Care by Subsector: Value 2001-2006
Table 66 Sales of Eye Care by Subsector: % Value Growth 2001-2006
Table 67 Eye Care Company Shares by Retail Value 2002-2006
Table 68 Eye Care Brand Shares by Retail Value 2003-2006
Table 69 Forecast Sales of Eye Care by Subsector: Value 2006-2011
Table 70 Forecast Sales of Eye Care by Subsector: % Value Growth 2006-2011
EAR CARE IN FRANCE
OVERVIEW
ADULT MOUTHCARE IN FRANCE
OVERVIEW
CALMING AND SLEEPING PRODUCTS IN FRANCE
OVERVIEW
WOUND TREATMENTS IN FRANCE
OVERVIEW
SECTOR DATA
Table 71 Sales of Wound Treatments by Subsector: Value 2001-2006
Table 72 Sales of Wound Treatments by Subsector: % Value Growth 2001-2006
Table 73 Wound Treatments Company Shares by Retail Value 2002-2006
Table 74 Wound Treatments Brand Shares by Retail Value 2003-2006
Table 75 Forecast Sales of Wound Treatments by Subsector: Value 2006-2011
Table 76 Forecast Sales of Wound Treatments by Subsector: % Value Growth 2006-2011
EMERGENCY CONTRACEPTION IN FRANCE
OVERVIEW
SECTOR DATA
Table 77 Sales of Emergency Contraception by Subsector: Value 2001-2006
Table 78 Sales of Emergency Contraception by Subsector: % Value Growth 2001-2006
Table 79 Forecast Sales of Emergency Contraception by Subsector: Value 2006-2011
Table 80 Forecast Sales of Emergency Contraception by Subsector: % Value Growth 2006-2011